Beneficial effects of the combination of BCc1 and Hep-S nanochelating-based medicines on IL-6 in hospitalized moderate COVID-19 adult patients: a randomized, double-blind, placebo-controlled clinical trial

ConclusionsIn conclusion, the combination of BCc1 and Hep-S inhibits IL-6 as a highly important and well-known cytokine in COVID-19 pathophysiology and presents a promising view for immunomodulation that can manage CSS.Trial registrationIranian Registry of Clinical TrialsRCT20170731035423N2. Registered on June 12, 2020.
Source: Trials - Category: Research Source Type: clinical trials